PDGFRA and gastrointestinal stromal tumor: The higher number of prior TKI treatments received by patients in Study 1002 patients reflects the use of available TKIs with the characteristic treatment resistance to PDGFRA D842V mutations before the approval of avapritinib for PDGFRA exon 18 and D842V-mutant GIST.